OvaScience (OVAS) Reports Q2 Loss of $0.51/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
OvaScience Reports Second Quarter 2017 Financial Results
August 3, 2017 4:02 PM EDTFertilization of Bovine EggPC Cell-Derived Egg in OvaTure Program on Track for Year-End
Completed Target Enrollment in OvaPrime Clinical Safety Study; Expect to Announce Initial Safety Data in First 20 Patients by Year-End
Sufficiently Funded to Support Operations into 1Q 2020, Enabling Key Milestones
Conference Call Today at 4:30 p.m. ET
WALTHAM, Mass.--(BUSINESS WIRE)-- OvaScienceSM (NASDAQ: OVAS), a fertility company focused on the discovery, development and commercialization of new treatment options, today reported financial results and provided a business update for the second quarter... More
